RESUMO
Influenza vaccination is recommended for all children 6 months of age and older who do not have contraindications. This article provides an overview of information concerning burden of influenza among children in the United States; US-licensed influenza vaccines; vaccine immunogenicity, effectiveness, and safety; and recent updates relevant to use of these vaccines in pediatric populations. Influenza antiviral medications are discussed. Details concerning vaccine-related topics may be found in the current US Centers for Disease Control and Prevention/Advisory Committee on Immunization Practices recommendations for use of influenza vaccines (https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html). Additional information on influenza antivirals is located at https://www.cdc.gov/flu/professionals/antivirals/index.htm.
Assuntos
Vacinas contra Influenza/administração & dosagem , Influenza Humana/prevenção & controle , Estações do Ano , Vacinação/estatística & dados numéricos , Comitês Consultivos , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Centers for Disease Control and Prevention, U.S. , Criança , Pré-Escolar , Efeitos Psicossociais da Doença , Humanos , Imunogenicidade da Vacina , Lactente , Vacinas contra Influenza/efeitos adversos , Influenza Humana/epidemiologia , Influenza Humana/virologia , Estados Unidos/epidemiologia , Vacinação/efeitos adversos , Potência de VacinaRESUMO
A case of enterococcal meningitis in a toddler is presented. The organism was highly resistant to all drugs previously used for pediatric Gram-positive meningitis. She was successfully treated with intraventricular and intravenous daptomycin and intravenous tigecycline. The organism was characterized as a member of CC17, a notorious emerging nosocomial clone of Enterococcus faecium.
